Half a year after toppling Genentech’s eye medicine giant Vabysmo in an early trial, Texas biotech Ollin Biosciences has lassoed a $330 million series B to push its winning contender through a multi-trial phase 3 gauntlet.
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
